市場調査レポート

脂質異常症治療薬の世界市場 - 2015〜2023年:スタチン、胆汁酸レジン、フィブリン酸、オメガ3脂肪酸誘導体、ニコチン酸 - 業界分析、市場規模、市場シェア、成長性、市場動向、将来予測

Dyslipidemia Drugs Market: (By Drug Class - Statins, Bile Acid Resins, Fibric Acid and Omega-3 Fatty Acid Derivatives, Niacins, Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

発行 Transparency Market Research 商品コード 338033
出版日 ページ情報 英文 101 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
脂質異常症治療薬の世界市場 - 2015〜2023年:スタチン、胆汁酸レジン、フィブリン酸、オメガ3脂肪酸誘導体、ニコチン酸 - 業界分析、市場規模、市場シェア、成長性、市場動向、将来予測 Dyslipidemia Drugs Market: (By Drug Class - Statins, Bile Acid Resins, Fibric Acid and Omega-3 Fatty Acid Derivatives, Niacins, Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
出版日: 2015年08月05日 ページ情報: 英文 101 Pages
概要

当レポートは、脂質異常症治療薬の世界市場を精査しており、市場成長促進要因、阻害要因、市場機会、市場の魅力度、市場競争状況等をさまざまな角度から包括的に検証し、現在の市場シナリオ分析と2015年から2023年までの市場予測を行っています。

第1章 序論

  • 当レポートについて
  • 市場分類
  • 調査手法
  • 略語一覧

第2章 エグゼクティブ・サマリー

  • 市場寸描:脂質異常症治療薬市場 - 2014年および2023年
  • 薬剤クラス別に見た脂質異常症治療薬市場 - 2014年
    • 比較分析:地域別に見た脂質異常症治療薬市場 - 2014年および2023年

第3章 市場概観

  • 概要
  • 疫学的分析:脂質異常症
  • 脂質異常症の病因
    • 主原因 (脂質異常症の遺伝的原因)
    • 二次的原因 (生活習慣上の要因)
  • 脂質異常症の診断
    • 血清脂質濃度測定 (総コレステロール、HDL、LDL、VLDL等)
    • その他の検査 (リポ蛋白検査、アポリポ蛋白質-B検査等)
    • 二次的原因のスクリーニングと診断
  • 脂質異常症治療の動向および将来の様相 (例:PCSK9、CETP阻害薬等)
  • 市場ダイナミクス
    • 市場成長促進要因
      • コレステロールおよびトリグリセリド脂質異常を有する人口の世界的増加により市場成長が促される
      • 肥満および糖尿病患者人口の増加により脂質異常症件数が増大する見通しであり、治療薬の需要が増大
      • 広範囲に及ぶ研究開発により脂質異常症治療薬に劇的な転換点がもたらされる
      • 広宣活動を通じた脂質異常症に対する認知度の向上
    • 市場成長阻害要因
      • 特許期限切れが差し迫っており、利幅が激減する
      • 新しい脂質異常症治療薬の製造中止
    • 市場機会
      • 新興諸国への商圏の拡大により大きなセールスの伸びが得られる
      • 脂質異常症に対するバイオ治療薬
      • 新しい部類の脂質異常症治療薬群からの薬剤分子開発で市場成長が促される
      • 新薬開発のための戦略的協業
  • 市場魅力度分析:地域別に見た脂質異常症治療薬市場
  • 脂質異常症治療薬世界市場における主要企業の市場シェア - 2014年
    • 企業別に見た脂質異常症治療薬世界市場の市場シェア分析 - 2014年

第4章 薬剤の種類別に見た脂質異常症治療薬市場

  • 序論
    • 薬剤の種類別に見た脂質異常症治療薬市場の収益額 - 2013〜2023年
  • スタチン
    • スタチン市場収益額 - 2013〜2023年
  • 胆汁酸レジン (コレスチラミン、コレスチポール、コレセベラム等)
    • 胆汁酸レジン市場収益額 - 2013〜2023年
  • フィブリン酸およびオメガ3脂肪酸誘導体 (フェノフィブラート、ジェムフィブロジル、Vascepa等)
    • フィブリン酸およびオメガ3脂肪酸誘導体市場収益額 - 2013〜2023年
  • ニコチン酸 (Niacor、Niaspan、Slo-Niacin等)
    • ニコチン酸市場収益額 - 2013〜2023年
  • その他 (ロバスタチンとニコチン酸、アトルバスタチンとアムロジピン、シンバスタチンとエゼチミブ、コレステロール吸収阻害薬等、各種薬剤の組み合わせ医薬品)
    • その他の医薬品市場収益額 - 2013〜2023年
  • 研究開発パイプライン上の薬剤
    • 薬剤の種類別に見たパイプライン段階医薬品による脂質異常症治療薬収益額 - 2013〜2023年
    • アナセトラピブ (MK-0859)
      • アナセトラピブ市場収益額 - 2018〜2023年
    • Evacetrapib (LY2484595)
      • Evacetrapib市場収益額 - 2017〜2023年
    • Praluent (Alirocumab)
      • Praluent市場収益額 - 2015〜2023年
    • Evolocumab (Repatha)
      • Evolocumab市場収益額 - 2015〜2023年
    • Bococizumab (RN316)
      • Bococizumab市場収益額 - 2019〜2023年

第5章 地域別に見た脂質異常症治療薬市場

  • 概要
    • 地域別に見た脂質異常症治療薬市場の収益額 - 2013〜2021年
  • 北米
    • 脂質異常症治療薬北米市場の国別収益額 - 2013〜2023年
  • 欧州
    • 脂質異常症治療薬欧州市場の国別収益額 - 2013〜2023年
  • アジア太平洋
    • 脂質異常症治療薬アジア太平洋市場の国別収益額 - 2013〜2023年
  • ラテンアメリカ
    • 脂質異常症治療薬ラテンアメリカ市場の国別収益額 - 2013〜2023年
  • 中東およびアフリカ地域
    • 中東およびアフリカ地域の脂質異常症治療薬市場の国別収益額 - 2013〜2023年

第6章 提言

  • 脂質異常症治療のための組み合わせ型治療薬の開発
  • 主要な薬剤開発企業は病院との協業を図るかあるいは製薬企業を買収しより効果的な脂質異常症治療薬を開発する必要あり
  • 世界的な企業は低から中所得レベルの諸国をターゲットとし、より大きな収益を上げるようにすべき

第7章 主要企業プロファイル

  • Abbott Laboratories
    • 会社概要
    • 財務状況
    • 製品ポートフォリオ
    • ビジネス戦略
    • 最近の事業展開
  • AstraZeneca plc
  • Amgen, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Mylan N.V.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • 塩野義製薬株式会社
  • 武田薬品工業株式会社
  • Teva Pharmaceutical Industries Ltd.
目次

Dyslipidemia is a chronic metabolic syndrome, characterized by improper level of low density lipoprotein, high density lipoprotein, and triglycerides. This study on the dyslipidemia drugs market involves the analysis of a wide range of therapeutics that help patients to treat lipid disorders. The dyslipidemia drugs market promises lucrative growth opportunities for pharmaceutical manufacturers due to increasing demand and prescriptions of these medications. According to the Centers for Disease Control and Prevention, cholesterol abnormalities are rapidly increasing in developed regions such as North America and Europe. Moreover, several articles published in open journals stated that demand for lipid lowering drugs is increasing in countries such as China, India, and Japan. However, loss of patent exclusivity of molecules such as Crestor, Zetia, and Vytorin is expected to hamper the growth of the market during the forecast period.

This report comprises a detailed study of various drug classes for the treatment of dyslipidemia. The dyslipidemia drugs market has been segmented into statins, bile acid resins, fibric acid derivatives, niacins, and others (combination drugs and cholesterol absorption inhibitors). The statins segment comprises combined market revenue of statin drugs such as atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, pitavastatin, and lovastatin. The bile acid resins segment included resins such as Cholestyramine, Colestipol, Colesevelam, and Cholybar. The fibric acid, and omega-3 fatty acid derivatives segment comprises generic drugs such as Fenofibrate, Clofibrate, and Bezafibrate. Other branded omega-3 fatty acids include Lovaza, Vascespa, and Omtryg. Niacins includes drugs such as Niaspan, Slo-Niacin, and Niacor. The others segment encompasses market analysis of combination drug therapies such as Advicor, Vytorin, and Caduet, as well as cholesterol inhibitor drugs. The market size and forecast for each drug class has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (% CAGR) for the forecast period from 2015 to 2023 for each drug class, considering 2013 to 2014 as the historical and base year, respectively.

By geography, the dyslipidemia drugs market has been studied for five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Each region has been further divided into major countries i.e., North America: the U.S. and Canada; Europe: Germany, France, the U.K. and Rest of Europe; Asia Pacific: China, Japan, India and Rest of APAC; Latin America: Brazil and Rest of LATAM; Middle East and Africa: South Africa and Rest of MEA. The market size and forecast for each region and country has been estimated for the period 2013 to 2023 in terms of revenue (USD million). The report also provides the compound annual growth rate (CAGR %) during the forecast period from 2015 to 2023 for all the regions and countries mentioned above.

The market overview section of the report discusses the market dynamics with respect to the market drivers, restraints, and opportunities. This section also covers information on epidemiology, etiology, dyslipidemia diagnostics, trends and future aspects, and market attractiveness analysis, by geography of the dyslipidemia drugs market. A list of recommendations for existing and new players to enter the market and enhance their position is also provided in the report. The report concludes with company profiles of key players operating in various drug classes of the market. Each company profile includes business overview, financial overview, product portfolio, business strategies, and recent developments of the respective market player. Prominent players in the dyslipidemia drugs market that have been profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Mylan N.V., Merck & Co., Inc., and AstraZeneca plc

The global dyslipidemia drugs market is segmented as follows:

Global Dyslipidemia Drugs Market, by Drug Class

  • Statins
  • Bile Acid Resins
  • Fibric Acid and Omega-3 Fatty Acid Derivatives
  • Niacins
  • Others (Combination Drugs and Cholesterol Absorption Inhibitors)

Global Dyslipidemia Drugs Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

Table of Contents

Chapter 1 - Introduction

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Sources
      • 1.3.1.1. Secondary Research
      • 1.3.1.2. Primary Research
      • 1.3.1.3. Assumption
  • 1.4. List of Abbreviations

Chapter 2 - Executive Summary

  • 2.1. Market Snapshot: Dyslipidemia Drugs Market (2014 & 2023)
  • 2.2. Dyslipidemia Drugs Market, by Drug Class, 2014 (USD Million)
    • 2.2.1 Comparative Analysis: Dyslipidemia Drugs Market, by Geography, 2014 and 2023 (Value %)

Chapter 3 - Market Overview

  • 3.1. Overview
  • 3.2. Epidemiology: Dyslipidemia
  • 3.3. Etiology of Dyslipidemia
    • 3.3.1. Primary Causes (genetic causes of dyslipidemia)
    • 3.3.2. Secondary Causes (lifestyle factors)
  • 3.4. Dyslipidemia Diagnostics
    • 3.4.1. Serum Lipid Profile Measurement (total cholesterol, HDL, LDL, VLDL, etc.)
    • 3.4.2. Other Tests (lipoprotein-A tests, apo lipoprotein B tests, etc.)
    • 3.4.3. Secondary Causes Screening and Diagnostics
  • 3.5. Trends and Future Aspects in Dyslipidemia Therapeutics (e.g. PCSK9, CETP inhibitors, etc.)
  • 3.6. Market Dynamics
    • 3.6.1. Market Drivers
      • 3.6.1.1. Global increasing prevalence of population with cholesterol and triglyceride abnormalities expected to propel the market
      • 3.6.1.2. Rise in obese and diabetic populations is expected to increase the incidence of dyslipidemia, and thus demand for dyslipidemia drugs
      • 3.6.1.3. Extensive research and development changes bring turnaround changes in the dyslipidemia drugs market
      • 3.6.1.4. Rising disease awareness through promotional activities
    • 3.6.2. Market Restraints
      • 3.6.2.1. Impending patent expirations to deplete profit margins
      • 3.6.2.2. Discontinuation of novel dyslipidemia drugs
    • 3.6.3. Opportunities
      • 3.6.3.1. Expanding footprint in emerging nations to generate high sales growth
      • 3.6.3.2. Biological therapies for the treatment of dyslipidemia
      • 3.6.3.3. Development of molecules from newer class of dyslipidemia drugs provide a ladder for growth
      • 3.6.3.4. Strategic collaborations for new drug development
  • 3.7. Market Attractiveness Analysis: Dyslipidemia Drugs Market, by Geography
  • 3.8. Market Share by Key Players of Global Dyslipidemia Drugs Market, 2014 (Value %)
    • 3.8.1. Global Dyslipidemia Drugs Market Share Analysis, by Key Players, 2014 (%)

Chapter 4 - Dyslipidemia Drugs Market, by Drug Class

  • 4.1. Introduction
    • 4.1.1. Dyslipidemia Drugs Market Revenue, by Drug Class, 2013 - 2023 (USD Million)
  • 4.2. Statins
    • 4.2.1. Statins Market Revenue, 2013 - 2023 (USD Million)
  • 4.3. Bile Acid Resins (Cholestyramine, Colestipol, Colesevelam, etc.)
    • 4.3.1. Bile Acid Resins Market Revenue, 2013 - 2023 (USD Million)
  • 4.4. Fibric Acid and Omega-3 Fatty Acid Derivatives (Fenofibrate, Gemfibrozil, Vascespa, etc.)
    • 4.4.1. Fibric Acid and Omega-3 Fatty Acid Derivatives Market Revenue, 2013 - 2023 (USD Million)
  • 4.5. Niacins (Niacor, Niaspan, Slo-Niacin, etc.)
    • 4.5.1. Niacins Market Revenue, 2013 - 2023 (USD Million)
  • 4.6. Others (Combination drugs such as lovastatin and niacin, atorvastatin and amlodipine, simvastatin and ezetimibe, cholesterol absorption inhibitors, etc.)
    • 4.6.1. Others Market Revenue, 2013 - 2023 (USD Million)
  • 4.7. Pipeline Drugs
    • 4.7.1. Dyslipidemia Drugs Market Revenue with Pipeline Drugs, by Drug Class, 2013 - 2023 (USD Million)
    • 4.7.2. Anacetrapib (MK-0859)
      • 4.7.2.1. Anacetrapib Market Revenue, 2018 - 2023 (USD Million)
    • 4.7.3. Evacetrapib (LY2484595)
      • 4.7.3.1. Evacetrapib Market Revenue, 2017 - 2023 (USD Million)
    • 4.7.4. Praluent (Alirocumab)
      • 4.7.4.1. Praluent Market Revenue, 2015 - 2023 (USD Million)
    • 4.7.5. Evolocumab (Repatha)
      • 4.7.5.1. Evolocumab Market Revenue, 2015 - 2023 (USD Million)
    • 4.7.6. Bococizumab (RN316)
      • 4.7.6.1. Bococizumab Market Revenue, 2019 - 2023 (USD Million)

Chapter 5 - Dyslipidemia Drugs Market, by Geography

  • 5.1. Overview
    • 5.1.1. Dyslipidemia Drugs Market Revenue, by Geography, 2013 - 2023 (USD Million)
  • 5.2. North America
    • 5.2.1. North America Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • 5.6. Middle East and Africa
    • 5.6.1. Middle East and Africa Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)

Chapter 6 - Recommendations

  • 6.1. Developing combination drugs for the treatment of dyslipidemia
  • 6.2. Major research-based drug developing companies must collaborate with hospitals or acquire pharma establishments to develop more effective dyslipidemia treatments
  • 6.3. Global players should target low to medium income countries to generate higher revenues

Chapter 7 - Company Profiles

  • 7.1. Abbott Laboratories
    • 7.1.1. Company Overview
    • 7.1.2. Financial Overview
    • 7.1.3. Product Portfolio
    • 7.1.4. Business Strategies
    • 7.1.5. Recent Developments
  • 7.2. AstraZeneca plc
    • 7.2.1. Company Overview
    • 7.2.2. Financial Overview
    • 7.2.3. Product Portfolio
    • 7.2.4. Business Strategies
    • 7.2.5. Recent Developments
  • 7.3. Amgen, Inc.
    • 7.3.1. Company Overview
    • 7.3.2. Financial Overview
    • 7.3.3. Product Portfolio
    • 7.3.4. Business Strategies
    • 7.3.5. Recent Developments
  • 7.4. Bayer AG
    • 7.4.1. Company Overview
    • 7.4.2. Financial Overview
    • 7.4.3. Product Portfolio
    • 7.4.4. Business Strategies
    • 7.4.5. Recent Developments
  • 7.5. Bristol-Myers Squibb Company
    • 7.5.1. Company Overview
    • 7.5.2. Financial Overview
    • 7.5.3. Product Portfolio
    • 7.5.4. Business Strategies
    • 7.5.5. Recent Developments
  • 7.6. Mylan N.V.
    • 7.6.1. Company Overview
    • 7.6.2. Financial Overview
    • 7.6.3. Product Portfolio
    • 7.6.4. Business Strategies
    • 7.6.5. Recent Developments
  • 7.7. Novartis AG
    • 7.7.1. Company Overview
    • 7.7.2. Financial Overview
    • 7.7.3. Product Portfolio
    • 7.7.4. Business Strategies
    • 7.7.5. Recent Developments
  • 7.8. Merck & Co., Inc.
    • 7.8.1. Company Overview
    • 7.8.2. Financial Overview
    • 7.8.3. Product Portfolio
    • 7.8.4. Business Strategies
    • 7.8.5. Recent Developments
  • 7.9. Pfizer, Inc.
    • 7.9.1. Company Overview
    • 7.9.2. Financial Overview
    • 7.9.3. Product Portfolio
    • 7.9.4. Business Strategies
    • 7.9.5. Recent Developments
  • 7.10. Shionogi & Co., Ltd.
    • 7.10.1. Company Overview
    • 7.10.2. Financial Overview
    • 7.10.3. Product Portfolio
    • 7.10.4. Business Strategies
    • 7.10.5. Recent Developments
  • 7.11. Takeda Pharmaceutical Company Limited
    • 7.11.1. Company Overview
    • 7.11.2. Financial Overview
    • 7.11.3. Product Portfolio
    • 7.11.4. Business Strategies
    • 7.11.5. Recent Developments
  • 7.12. Teva Pharmaceutical Industries Ltd.
    • 7.12.1. Company Overview
    • 7.12.2. Financial Overview
    • 7.12.3. Product Portfolio
    • 7.12.4. Business Strategies
    • 7.12.5. Recent Developments

List of Figures

  • FIG. 1: Dyslipidemia Drugs Market: Market Segmentation
  • FIG. 2: Dyslipidemia Drugs Market, by Drug Class, 2014 (USD Million)
  • FIG. 3: Comparative Analysis: Dyslipidemia Drugs Market, by Geography, 2014 and 2023 (Value %)
  • FIG. 4: Market Attractiveness Analysis: Dyslipidemia Drugs Market, by Geography
  • FIG. 5: Global Dyslipidemia Drugs Market: Market Share, by Key Players, 2014 (%)
  • FIG. 6: Statins Market Revenue, 2013 - 2023 (USD Million)
  • FIG. 7: Bile Acid Resins Market Revenue, 2013 - 2023 (USD Million)
  • FIG. 8: Fibric Acid and Omega-3 Fatty Acid Derivatives Market Revenue, 2013 - 2023 (USD Million)
  • FIG. 9: Niacins Market Revenue, 2013 - 2023 (USD Million)
  • FIG. 10: Others Market Revenue, 2013 - 2023 (USD Million)
  • FIG. 11: Anacetrapib Market Revenue, 2018 - 2023 (USD Million)
  • FIG. 12: Evacetrapib Market Revenue, 2017 - 2023 (USD Million)
  • FIG. 13: Praluent Market Revenue, 2015 - 2023 (USD Million)
  • FIG. 14: Evolocumab Market Revenue, 2015 - 2023 (USD Million)
  • FIG. 15: Bococizumab Market Revenue, 2019 - 2023 (USD Million)
  • FIG. 16: Abbott Laboratories: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 17: AstraZeneca plc: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 18: Amgen, Inc.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 19: Bayer AG: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 20: Bristol-Myers Squibb Company: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 21: Mylan N.V.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 22: Novartis AG: Annual Revenues, 2012 - 2014 (USD Million)
  • FIG. 23: Merck & Co., Inc.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 24: Pfizer, Inc.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 25: Shionogi & Co., Ltd.: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 26: Takeda Pharmaceutical Company Limited: Annual Revenue, 2012 - 2014 (USD Million)
  • FIG. 27: Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2012 - 2014 (USD Million)

List of Tables

  • TABLE 1: List of Abbreviations
  • TABLE 2: Market Snapshot: Dyslipidemia Drugs Market (2014 & 2023)
  • TABLE 3: Number of People with Diabetes (20 Years - 79 years), by Country/Territory, 2013 (Millions)
  • TABLE 4: Impact Analysis of Market Drivers
  • TABLE 5: Impact Analysis of Market Restraints
  • TABLE 6: Dyslipidemia Drugs Market Revenue, by Drug Class, 2013 - 2023 (USD Million)
  • TABLE 7: Dyslipidemia Drugs Market Revenue with Pipeline Drugs, by Drug Class, 2013 - 2023 (USD Million)
  • TABLE 8: Dyslipidemia Drugs Market Revenue, by Geography, 2013 - 2023 (USD Million)
  • TABLE 9: North America Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • TABLE 10: Europe Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • TABLE 11: Asia Pacific Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • TABLE 12: Latin America Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
  • TABLE 13: Middle East and Africa Dyslipidemia Drugs Market Revenue, by Country, 2013 - 2023 (USD Million)
Back to Top